Pseudotypes of vesicular stomatitis virus (VSV) bearing envelope antigens of human T-cell leukemia virus (HTLV) types 1 and 2 were prepared by propagating VSV in cells lines productively infected with HTLV. Plaque assays of VSV(HTLV) pseudotypes were employed to determine the presence of (i) HTLV receptors on cells and (it) neutralizing antibodies in the serum of patients with adult T-cell leukemialymphoma (ATLL). Cell surface receptors for HTLV-1 and HTLV-2 were found on nonlymphoid cells of human and mammalian origin. Neutralizing antibodies specific to VSV(HTLV-1) were found in sera of ATLL patients in titers varying from 1:50 to 1:30,000 and did not correlate closely with antibody titers for internal viral antigens. Sera from ATLL patients in the United Kingdom (Caribbean immigrants), United States, and Japan completely neutralized VSV(HTLV-1), indicating that the HTLV isolates from these distinct geographic regions represent a single envelope serotype. Neutralization of VSV(HTLV-1) was more specific and more sensitive than assays of syncytium inhibition. No crossneutralization was observed between bovine leukosis virus and HTLV, and only limited cross-reaction was found for envelope antigens of HTLV-1 and HTLV-2. These studies show that VSV(HTLV) pseudotypes can be readily used to screen for neutralizing antibodies in patients' sera and to distinguish HTLV envelope serotypes.
HTLV type 2 (HTLV-2), has been isolated from an American patient with T-cell hairy cell leukemia (14) .
Like many naturally occurring strains of animal retroviruses, a simple, quantitative bioassay of HTLV has proved difficult because the virus is not directly cytopathic or transforming for monolayer cells in culture. A syncytium assay of HTLV production (15) (16) (17) is not readily adaptable to a quantitative plaque assay because the in vitro infectivity of cellfree HTLV preparations is very low (18) . An alternative approach is to use an indirect assay of pseudotypes rather than the virus itself. Pseudotypes are phenotypically mixed virions carrying the genome of one virus and the coat proteins of another. The most widely used pseudotype systems for retroviruses employ either related retrovirus genomes carrying oncogenes, which can be titrated by a focal cell transformation assay, or the unrelated rhabdovirus, vesicular stomatitis virus (VSV), which is titrated by plaque assay (19, 20) . We have adopted the VSV system for HTLV studies.
When cells chronically infected with retroviruses are superinfected with VSV, a proportion of the progeny VSV particles bear the envelope glycoproteins of the retrovirus (20) (21) (22) . Core antigens of the retrovirus are not assembled into VS virions. The VSV pseudotypes resist neutralization by anti-VSV antibodies but are sensitive to neutralizing antibodies specific to the retrovirus donating the envelope antigens. The host range for viral penetration of pseudotypes is restricted to cells bearing receptors for the retrovirus. Following penetration and uncoating, however, the VSV genome contained in the pseudotype particle replicates to produce nonpseudotype progeny. Thus, a cytopathic plaque assay of VSV pseudotypes can be used to determine receptor expression, receptor interference, and neutralizing antibodies specific to the retrovirus encoding the envelope glycoproteins.
VSV pseudotype particles have been employed to study the biological properties of the envelope glycoproteins of avian leukosis and reticuloendotheliosis viruses (21) (22) (23) (24) , murine leukemia viruses (21, 25, 26) , murine mammary tumor virus (27, 28) , bovine leukosis virus (BLV) (29) , and primate retroviruses (30, 31) . Here we report the production of VSV(HTLV) pseudotype particles and their neutralization by human sera.
MATERIALS AND METHODS
Viruses and Cells. VSV. VSV, Indiana serotype, a wildtype clone recently plaque-purified, was used for pseudotype production (24) .
HTLV-1. HTLV-producing MT2 cells (5) were obtained from I. Miyoshi (Kochi, Japan). HUT78, HUT102, C10/MJ2, C91/PL, and MT1 cells (3, 32) were obtained from R. C. Gallo and M. Popovic Human, mink, and feline cells were equally sensitive to VSV(HTLV-1), whereas bovine MDBK cells were completely resistant (data not shown), indicating that cell surface receptors for HTLV-1 are widespread but not universal among mammalian cell types. A more detailed analysis of pseudotype host range will be reported elsewhere (33) .
Propagation of Pseudotypes in Further HTLV-Producing Cells. Pseudotype formation was investigated with a number of HTLV isolates, including HTLV-2, and also with BLV. Table 1 shows that specific pseudotypes were obtained with VSV propagated in cells infected with the PL isolate of HTLV-1, whereas other HTLV-1 isolates did not unequivocally yield VSV pseudotypes. Some pfu surviving anti-VSV were obtained with MT2 and C10/MJ2 (cells that produce more HTLV than the other HTLV-1-infected cells), but they were not neutralized by high-titer sera of either American or Japanese ATLL patients. Therefore, the surviving pfu should not be strictly defined as pseudotypes, although their plating efficiency was reduced on MDBK cells lacking HTLV receptors (data not shown). However, specific pseudotypes were obtained with HTLV-2 (MO isolate in C1218M and Tonl cells) and BLV. The VSV(HTLV-2) stocks had a higher plating efficiency on feline CCC cells than on HOS or mink cells, and CCC cells were therefore used for all comparative assays involving HTLV-2. Table 3 compares the pseudotype neutralizing properties and syncytium inhibitory activities of sera from individuals naturally infected with HTLV-1, HTLV-2, a simian virus closely related to HTLV, and BLV. Approximately 75% ATLL sera have antibodies specifically inhibiting HTLV-1 syncytia, whereas 25% sera show equivalent titers for inhibition of both HTLV-1 and HTLV-2 syncytia (17) . Sera H0423 and F4093 represent the first category and sera F4387 and HS1 the second. Serum MO is from the patient with hairy cell leukemia from whom HTLV-2 was isolated (14) . (35) .
The data presented in Table 3 show that the envelope antigens of HTLV-1, HTLV-2, and BLV can be clearly differentiated serologically in pseudotype neutralization assays. No cross-reaction between BLV and either HTLV strain was observed with sera showing high titers for the envelope antigens of homologous viruses. The high-titer HTLV-1 sera had The serum titers are the reciprocal of the highest dilution causing >80%o reduction of syncytia or pseudotype pfu.
much lower titers for VSV(HTLV-2), and conversely MO serum was specific for HTLV-2. The human, chimpanzee, and vervet sera, that showed equal cross-reaction with HTLV-1 and HTLV-2 in syncytium inhibition assays, all exhibited markedly stronger neutralization of VSV(HTLV-1) than VSV(HTLV-2).
DISCUSSION
We have demonstrated the use of VSV pseudotypes to investigate HTLV-1 and HTLV-2 envelope antigens, including titrations of human sera for neutralization of infectivity. VSV(HTLV) pseudotype formation was efficient in HTLV-1-producing HOS/PL and C91/PL and HTLV-2-producing C1218M and Tonl cells but was inconclusive in other HTLV-1-producing T cells and in HOS/MT2 cells. Pseudotype yields from HOS/PL cells were equivalent to titers reported with other primate retroviruses (30) and BLV (29) but were 1/100th of the titers attainable with avian leukosis viruses (24) . Experimentation with mixed infections of VSV and HTLV may represent a potential biohazard greater than laboratory manipulation of HTLV alone. When rhabdoviruses and retroviruses are propagated in the same cells, reciprocal phenotypic mixing takes place (36, 37) . Thus, HTLV(VSV) particles bearing stable VSV glycoproteins may be produced as well as VSV(HTLV) pseudotypes. These "reverse" pseudotypes are likely to be more infectious than HTLV itself, which may require cell-to-cell contact for transfer.
The ability of VSV(HTLV) to plaque on several nonlymphoid cell types demonstrates that the apparent T-cell tropism of HTLV is not due to the lack of receptors on other cell types, and at least one nonlymphoid line, HOS, is permissive for HTLV replication (18) . Receptor 
